This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Soleno Therapeutics Faces Securities...
Regulatory securities fraud lawsuit

Soleno Therapeutics Faces Securities Fraud Lawsuit

Analysis based on 7 articles · First reported Mar 12, 2026 · Last updated Mar 26, 2026

Sentiment
-20
Attention
2
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is impacted by the potential for a decline in Soleno Therapeutics' stock price due to the securities fraud lawsuit. This event highlights the risks associated with clinical trial disclosures for biotechnology companies.

Biotechnology Legal Services
Event Summary

Bernstein Liebhard LLP has announced a securities fraud class action lawsuit against Soleno Therapeutics, Inc. on behalf of investors who purchased shares between March 26, 2025, and August 4, 2025. The lawsuit alleges that Soleno Therapeutics and its senior officers made misrepresentations concerning the company's Phase 3 clinical trial program for DCCR. Investors who suffered losses are encouraged to join the lawsuit, with a lead plaintiff deadline of May 5, 2026. The lawsuit was filed in the United States===United States District Court for the Northern District of California.

Key Actions
90 Bernstein Liebhard LLP commenced securities fraud class action lawsuit Soleno Therapeutics
80 Soleno Therapeutics made alleged misrepresentations regarding DCCR Phase 3 clinical trial
Entities Involved
stock
Soleno Therapeutics
Soleno Therapeutics is facing a securities fraud class action lawsuit for alleged misrepresentations concerning its Phase 3 clinical trial program for DCCR, which could negatively impact its stock price and reputation.
Importance 100 Sentiment -50
priv
Bernstein Liebhard LLP
Bernstein Liebhard LLP is initiating a securities fraud class action lawsuit against Soleno Therapeutics, Inc., representing investors who allegedly suffered losses due to misrepresentations.
Importance 60 Sentiment 20
govactor
United States===United States District Court for the Northern District of California
The United States===United States District Court for the Northern District of California is the venue where the securities fraud class action lawsuit against Soleno Therapeutics was filed.
Importance 30 Sentiment 0
per
Peter Allocco
Peter Allocco is the Investor Relations Manager at Bernstein Liebhard LLP and serves as a contact for investors interested in the Soleno Therapeutics lawsuit.
Importance 10 Sentiment 0
Relationships
Bernstein Liebhard LLP related ↔ Soleno Therapeutics
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.